Vaxcyte (PCVX) announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi (SNY), to its Board of Directors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte initiated with an Overweight at Cantor Fitzgerald
- Biotech Alert: Searches spiking for these stocks today
- Vaxcyte’s Promising Prospects: Buy Rating Reinforced by Positive Phase 2 Data and Strategic Expansion
- Optimistic Buy Rating for Vaxcyte Amid Vaccine Development Challenges and Strategic Adjustments
- BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’